In particular, the PSMA gene, a valuable biomarker for predicting the outcome in patients with prostate cancer, was detected in CTCs of many metastatic prostate cancer patients (57.14% (8/14 patients) at CTC-μChip and 42.86% (6/14 patients) at AdnaTest) (Figure 6c). This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.